Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The AC-055-302/SERAPHIN study will be an event-driven Phase III study, comparing two
different doses of macitentan (ACT-064992) (3 and 10 mg) vs placebo in patients with
symptomatic PAH. The main study objective is to demonstrate that macitentan (ACT-064992)
prolongs time to the first morbidity or mortality event, and to evaluate the benefit/risk
profile of macitentan (ACT-064992) in the treatment of patients with symptomatic PAH.